{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:16:03Z","timestamp":1788261363231,"version":"build-2803163510"},"reference-count":184,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006694","name":"Italian Association Against Leukemia-Lymphoma and Myeloma ONLUS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.blre.2026.101412","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:37:25Z","timestamp":1781969845000},"page":"101412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group"],"prefix":"10.1016","volume":"77","author":[{"given":"Francesco","family":"Marchesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Girmenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Maria","family":"Trecarichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Piciocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Busca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Candoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Delia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ilaria","family":"Del Principe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Fianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Stefano","family":"Fracchiolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Tumbarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"30","key":"10.1016\/j.blre.2026.101412_bb0005","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2026.101412_bb0010","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.blre.2026.101412_bb0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.6004\/jnccn.2024.0056","article-title":"Prevention and treatment of cancer-related infections, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Baden","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-020-04297-8","volume":"100","author":"Christopeit","year":"2021","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.blre.2026.101412_bb0025","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","article-title":"Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European conference on infections in leukemia (ECIL)","volume":"39","author":"Pagano","year":"2025","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2026.101412_bb0030","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the infectious diseases working party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"Stemler","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.blre.2026.101412_bb0035","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41375-022-01556-7","volume":"36","author":"Maschmeyer","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2026.101412_bb0040","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2352-3026(22)00073-4","article-title":"Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association","volume":"9","author":"Stemler","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Suppl. 7","key":"10.1016\/j.blre.2026.101412_bb0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/imj.15588","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021","volume":"51","author":"Teh","year":"2021","journal-title":"Intern Med J"},{"issue":"27","key":"10.1016\/j.blre.2026.101412_bb0050","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.20.00158","article-title":"Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with Cancer and hematopoietic stem-cell transplantation recipients","volume":"38","author":"Lehrnbecher","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2026.101412_bb0055","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European conference on infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2026.101412_bb0060","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.blre.2026.101412_bb0065","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European conference on infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation","volume":"15","author":"Groll","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0070","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","article-title":"Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines","volume":"76","author":"Mikulska","year":"2018","journal-title":"J Infect"},{"issue":"11","key":"10.1016\/j.blre.2026.101412_bb0075","first-page":"3496","article-title":"Towards personalized prevention of herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an Italian expert panel","volume":"109","author":"Girmenia","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2026.101412_bb0080","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00277-021-04746-y","volume":"101","author":"Henze","year":"2022","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.blre.2026.101412_bb0085","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S1473-3099(25)00365-2","article-title":"Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European conference on infections in Leukaemia","volume":"26","author":"Von Lilienfeld-Toal","year":"2026","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.blre.2026.101412_bb0090","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/s41375-025-02649-9","article-title":"Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European conference on infections in Leukaemia (ECIL-10)","volume":"39","author":"Cesaro","year":"2025","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2026.101412_bb0095","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1016\/S1473-3099(18)30601-7","article-title":"Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European conference on infections in Leukaemia (ECIL 7)","volume":"19","author":"Mikulska","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.blre.2026.101412_bb0100","series-title":"Quinolone- and fluoroquinolone-containing medicinal products","author":"EMA","year":"2026"},{"key":"10.1016\/j.blre.2026.101412_bb0105","series-title":"FDA drug safety communication: FDA updates warnings on oral and injectable fluoroquinolone antibiotics","author":"FDA","year":"2026"},{"issue":"6","key":"10.1016\/j.blre.2026.101412_bb0110","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1016\/S1473-3099(25)00619-X","article-title":"Empirical and targeted antimicrobial therapy in patients with febrile neutropenia and haematological malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference on Infections in Leukaemia","volume":"26","author":"Averbuch","year":"2026","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.blre.2026.101412_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106571","article-title":"Epidemiology of resistant bacterial infections in patients with hematological malignancies or undergoing hematopoietic cell transplantation in Europe: a systematic review by the European conference on infections in leukemia (ECIL)","volume":"91","author":"Baccelli","year":"2025","journal-title":"J Infect"},{"key":"10.1016\/j.blre.2026.101412_bb0120","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.70358","article-title":"Prevention and management of febrile neutropenia in acute myeloid leukaemia and hogher risk myelodysplastic syndrome: an international survey of current practice","author":"MacPhail","year":"2026","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2026.101412_bb0125","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0130","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"1","author":"Gafter-Gvili","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.blre.2026.101412_bb0135","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/cid\/ciab404","article-title":"Colonization with fluoroquinolone-resistant enterobacterales decreases the effectiveness of fluoroquinolone prophylaxis in hematopoietic cell transplant recipients","volume":"73","author":"Satlin","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.blre.2026.101412_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106806","article-title":"Bloodstream infections due to gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey","volume":"61","author":"Trecarichi","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0145","doi-asserted-by":"crossref","first-page":"34908","DOI":"10.1038\/s41598-025-18714-3","article-title":"Concentrations of ciprofloxacin in food defined as safe alter the gut microbiome and ciprofloxacin susceptibility in humans: an interventional clinical study","volume":"15","author":"Manoharan-Basil","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0150","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2442523","article-title":"A modelling framework to characterize the impact of antibiotics on the gut microbiota diversity","volume":"17","author":"Olivares","year":"2025","journal-title":"Gut Microbes"},{"key":"10.1016\/j.blre.2026.101412_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102593","article-title":"Fluconazole and levofloxacin prophylaxis are ineffective strategies for preventing infections in acute myeloid leukemia patients undergoing chemotherapy","volume":"91","author":"Soldi","year":"2024","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0160","article-title":"Improved treatment outcomes with modified induction therapy in acute myeloid leukemia (AML): a retrospective observational study from a regional cancer center","volume":"16","author":"Iqbal","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0165","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41375-022-01786-9","article-title":"Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms","volume":"37","author":"Walti","year":"2023","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2026.101412_bb0170","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.26991","article-title":"Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia","volume":"98","author":"Matthews","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101412_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107346","article-title":"FLAG based v\/s standard 3 + 7 induction therapy in treatment na\u00efve acute myeloid leukemia: time to think \u00abbeyond anthracyclines\u00bb","volume":"132","author":"Shaikh","year":"2023","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101412_bb0180","article-title":"Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia","volume":"16","author":"Sherif","year":"2021","journal-title":"Leuk Res Rep"},{"issue":"3","key":"10.1016\/j.blre.2026.101412_bb0185","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/10428194.2019.1688320","article-title":"Consolidation outcomes in CPX-351 versus cytarabine\/daunorubicin-treated older patients with high-risk\/secondary acute myeloid leukemia","volume":"61","author":"Kolitz","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101412_bb0190","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.leukres.2018.08.005","article-title":"Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7+3) in newly diagnosed high-risk acute myeloid leukemia (AML)","volume":"72","author":"Zeidner","year":"2018","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.blre.2026.101412_bb0195","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdy030","article-title":"Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients","volume":"29","author":"R\u00f6llig","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2026.101412_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2017.02.003","article-title":"Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies","volume":"57","author":"Kang","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101412_bb0205","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.leukres.2017.08.009","article-title":"Timed sequential therapy for acute myelogenous leukemia: results of a retrospective study of 301 patients and review of the literature","volume":"61","author":"Norsworthy","year":"2017","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.blre.2026.101412_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224465","article-title":"Bloodstream infections caused by Escherichia coli in onco-haematological patients: risk factors and mortality in an Italian prospective survey","volume":"14","author":"Trecarichi","year":"2019","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0215","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/bjh.70275","article-title":"Real-world experience with CPX-351 for secondary acute myeloid leukaemia: comparison with FLAG-IDA in a propensity score matching analysis","volume":"208","author":"Perusini","year":"2026","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2026.101412_bb0220","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/bjh.19622","article-title":"REST-UK: real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK","volume":"205","author":"Mehta","year":"2024","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2026.101412_bb0225","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s12185-024-03733-z","article-title":"A phase 1\/2 study of NS-87\/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia","volume":"119","author":"Usuki","year":"2024","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2026.101412_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1272072","article-title":"Impact of different chemotherapy regimens on intestinal mucosal injury assessed with bedside ultrasound: a study in 213 AML patients","volume":"13","author":"Benedetti","year":"2023","journal-title":"Front Oncol"},{"issue":"13","key":"10.1016\/j.blre.2026.101412_bb0235","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.3390\/cancers15133457","article-title":"Multicenter observational retrospective study on febrile events in patients with acute myeloid leukemia treated with Cpx-351 in \u00abreal-life\u00bb: the SEIFEM experience","volume":"15","author":"Fianchi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"16","key":"10.1016\/j.blre.2026.101412_bb0240","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial","volume":"7","author":"Othman","year":"2023","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.blre.2026.101412_bb0245","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0250","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-022-01361-w","article-title":"Efficacy and safety of CPX-351 versus 7+3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk\/secondary AML: post hoc analysis of a randomized, phase 3 trial","volume":"15","author":"Cortes","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.blre.2026.101412_bb0255","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1080\/10428194.2022.2092855","article-title":"Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine\/daunorubicin with and without the addition of cladribine","volume":"63","author":"Klingler","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0260","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","article-title":"Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort","volume":"5","author":"Chiche","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.blre.2026.101412_bb0265","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/bloodadvances.2020003510","article-title":"Older adults with newly diagnosed high-risk\/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses","volume":"5","author":"Lin","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.blre.2026.101412_bb0270","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41408-021-00558-5","article-title":"Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia","volume":"11","author":"Rautenberg","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.blre.2026.101412_bb0275","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1080\/10428194.2021.1907378","article-title":"Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia","volume":"62","author":"Benitez","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.blre.2026.101412_bb0280","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1038\/s41375-020-0916-8","article-title":"Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality","volume":"34","author":"Issa","year":"2020","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.blre.2026.101412_bb0285","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional Cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0290","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cncr.28974","article-title":"Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML","volume":"121","author":"Cortes","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.blre.2026.101412_bb0295","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood.2025031006","article-title":"CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial","volume":"147","author":"Knapper","year":"2026","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2026.101412_bb0300","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41375-025-02700-9","article-title":"Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis","volume":"39","author":"Ronnacker","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101412_bb0305","article-title":"Real-world efficacy and safety of gemtuzumab ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed acute myeloid leukemia (AML) patients. A retrospective multicenter study of \u00abRete Ematologica Pugliese\u00bb (REP)","volume":"24","author":"Dargenio","year":"2025","journal-title":"Leuk Res Rep"},{"issue":"10","key":"10.1016\/j.blre.2026.101412_bb0310","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1200\/JCO.23.00943","article-title":"Fludarabine, Cytarabine, granulocyte Colony-stimulating factor, and Idarubicin with Gemtuzumab Ozogamicin improves event-free survival in younger patients with newly diagnosed AML and overall survival in patients with NPM1 and FLT3 mutations","volume":"42","author":"Russell","year":"2024","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.blre.2026.101412_bb0315","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.2023020630","article-title":"Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial","volume":"142","author":"Freeman","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2026.101412_bb0320","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3026(23)00089-3","article-title":"Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial","volume":"10","author":"D\u00f6hner","year":"2023","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.blre.2026.101412_bb0325","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.19.01406","article-title":"Gemtuzumab Ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 phase III study","volume":"38","author":"Schlenk","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0330","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0335","first-page":"72","article-title":"Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed\/refractory acute myeloid leukemia","volume":"109","author":"Shahswar","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101412_bb0340","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41375-023-01930-z","article-title":"Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis","volume":"37","author":"Santoni","year":"2023","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2026.101412_bb0345","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0350","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/cancers13010034","article-title":"Fludarabine, high-dose Cytarabine and Idarubicin-based induction may overcome the negative prognostic impact of FLT3-ITD in NPM1 mutated AML, irrespectively of FLT3-ITD allelic burden","volume":"13","author":"Minetto","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"25","key":"10.1016\/j.blre.2026.101412_bb0355","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2026.101412_bb0360","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1080\/10428194.2018.1508670","article-title":"FLAG salvage therapy combined with idarubicin in relapsed\/refractory acute myeloid leukemia","volume":"60","author":"Westhus","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.blre.2026.101412_bb0365","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ajh.24391","article-title":"High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: a critical review of a 10-year, single-center experience in younger, non M3 AML patients","volume":"91","author":"Guolo","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0370","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO-25-01841","article-title":"Quizartinib for newly diagnosed FLT3-internal tandem duplication-negative AML: the randomized, double-blind, placebo-controlled, phase II QUIWI study","volume":"44","author":"Montesinos","year":"2026","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.blre.2026.101412_bb0375","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1182\/bloodadvances.2025017244","article-title":"Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML","volume":"9","author":"Russell","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0380","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.27547","article-title":"Efficacy of Midostaurin combined with intensive chemotherapy in core binding factor leukemia: a phase II clinical trial","volume":"100","author":"Cairoli","year":"2025","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.blre.2026.101412_bb0385","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/bjh.19436","article-title":"Gemtuzumab ozogamicin plus midostaurin in combination with standard \u00ab7 + 3\u00bb induction therapy in newly diagnosed AML: results from the SAL-MODULE phase I study","volume":"204","author":"R\u00f6llig","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2026.101412_bb0390","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00277-024-05614-1","article-title":"Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center","volume":"103","author":"Kennedy","year":"2024","journal-title":"Ann Hematol"},{"issue":"23","key":"10.1016\/j.blre.2026.101412_bb0395","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.2023020301","article-title":"Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG","volume":"142","author":"Loo","year":"2023","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.blre.2026.101412_bb0400","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1200\/JCO.22.02721","article-title":"Gilteritinib in combination with induction and consolidation chemotherapy and as maintenance therapy: a phase IB study in patients with newly diagnosed AML","volume":"41","author":"Pratz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.blre.2026.101412_bb0405","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1182\/bloodadvances.2023010392","article-title":"Phase 1\/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML","volume":"7","author":"Halpern","year":"2023","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.blre.2026.101412_bb0410","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1182\/bloodadvances.2023009847","article-title":"Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial","volume":"7","author":"Sierra","year":"2023","journal-title":"Blood Adv"},{"issue":"10388","key":"10.1016\/j.blre.2026.101412_bb0415","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-first): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.blre.2026.101412_bb0420","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1182\/bloodadvances.2022007223","article-title":"Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications","volume":"6","author":"D\u00f6hner","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.blre.2026.101412_bb0425","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3390\/jof8060583","article-title":"High incidence of invasive fungal diseases in patients with FLT3-mutated AML treated with Midostaurin: results of a multicenter observational SEIFEM study","volume":"8","author":"Cattaneo","year":"2022","journal-title":"J Fungi (Basel)"},{"issue":"5","key":"10.1016\/j.blre.2026.101412_bb0430","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1016\/j.clml.2020.10.014","article-title":"Invasive Mold infections in FLT3-mutated acute myeloid leukemia","volume":"21","author":"Phoompoung","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101412_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106497","article-title":"Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapsed or refractory FLT3 positive acute myeloid leukemia patients","volume":"101","author":"Marconi","year":"2021","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.blre.2026.101412_bb0440","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0445","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ajh.24974","article-title":"Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia","volume":"93","author":"Altman","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.blre.2026.101412_bb0450","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2026.101412_bb0455","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood-2016-07-730648","article-title":"A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML","volume":"129","author":"Knapper","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0460","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35662","article-title":"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia","volume":"131","author":"Jen","year":"2025","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0465","doi-asserted-by":"crossref","first-page":"19987","DOI":"10.1038\/s41598-024-71082-2","article-title":"Analysis of early death in critically ill patients with acute promyelocytic leukaemia in the HICU","volume":"14","author":"Li","year":"2024","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0470","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/bjh.18618","article-title":"Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-Centre study","volume":"201","author":"Singh","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0475","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12885-023-10612-z","article-title":"Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021","volume":"23","author":"Gill","year":"2023","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.blre.2026.101412_bb0480","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-022-00753-y","article-title":"An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)","volume":"12","author":"Wang","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0485","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13045-022-01368-3","article-title":"Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia","volume":"15","author":"Ma","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101412_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.614721","article-title":"Efficacy and tolerability of first line arsenic trioxide in combination with all-trans retinoic acid in patients with acute Promyelocytic leukemia: real life experience","volume":"11","author":"Autore","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101412_bb0495","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.762653","article-title":"Early death and survival of patients with acute promyelocytic leukemia in ATRA plus arsenic era: a population-based study","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101412_bb0500","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.3324\/haematol.2021.278722","article-title":"Characteristics and outcome of patients with low\u2212\/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study","volume":"106","author":"Kayser","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101412_bb0505","article-title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","volume":"118","author":"Chen","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2026.101412_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106569","article-title":"Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy","volume":"106","author":"Glass","year":"2021","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.blre.2026.101412_bb0515","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1080\/10428194.2020.1838507","article-title":"Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia","volume":"62","author":"Freyer","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.blre.2026.101412_bb0520","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1182\/bloodadvances.2019001278","article-title":"A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)","volume":"4","author":"Lancet","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.blre.2026.101412_bb0525","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(18)30295-X","article-title":"Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.blre.2026.101412_bb0530","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s12288-017-0894-9","article-title":"Invasive fungal infections in acute Promyelocytic leukemia on dual differentiating agents: real world data","volume":"34","author":"Yanamandra","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"6","key":"10.1016\/j.blre.2026.101412_bb0535","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute Promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101412_bb0540","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","article-title":"Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab","volume":"129","author":"Abaza","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101412_bb0545","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.13308","article-title":"Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry","volume":"170","author":"Pagano","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101412_bb0550","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3026(15)00115-5","article-title":"Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and lymphoma group (ALLG) APML4 study: a non-randomised phase 2 trial","volume":"2","author":"Iland","year":"2015","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.blre.2026.101412_bb0555","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2018-05-851824","article-title":"Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial","volume":"132","author":"Russel","year":"2018","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2026.101412_bb0560","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0565","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000353126","article-title":"High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia","volume":"131","author":"Yamakura","year":"2014","journal-title":"Acta Haematol"},{"issue":"33","key":"10.1016\/j.blre.2026.101412_bb0570","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1200\/JCO.2013.51.2913","article-title":"Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide","volume":"32","author":"Roboz","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2026.101412_bb0575","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf105","article-title":"Levofloxacin to prevent bacterial infection in patients with acute myeloid leukemia treated by Venetoclax and Azacitidine: a Toulouse-Bordeaux DATAML registry study","volume":"12","author":"Brousse","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.blre.2026.101412_bb0580","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/bjh.19670","article-title":"Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis","volume":"205","author":"Weinbergerov\u00e1","year":"2024","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2026.101412_bb0585","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1002\/ajh.26846","article-title":"Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax","volume":"98","author":"Candoni","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.blre.2026.101412_bb0590","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac486","article-title":"Incidence of invasive fungal infections in patients with previously untreated acute myeloid leukemia receiving Venetoclax and Azacitidine","volume":"9","author":"Zhang","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.blre.2026.101412_bb0595","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1080\/10428194.2022.2047964","article-title":"Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax","volume":"63","author":"Chen","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101412_bb0600","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/cncr.33508","article-title":"Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia","volume":"127","author":"Rausch","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2026.101412_bb0605","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1404322","article-title":"No advantage of antimicrobial prophylaxis in AML\/MDS\/CMML patients treated with azacitidine-a prospective multicenter study by the polish adult leukemia group","volume":"14","author":"M\u0105dry","year":"2024","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.blre.2026.101412_bb0610","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00432-022-03995-2","article-title":"Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia","volume":"149","author":"Tober","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"16","key":"10.1016\/j.blre.2026.101412_bb0615","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0620","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/ejh.13769","article-title":"Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: a multicenter international study","volume":"109","author":"Ito","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2026.101412_bb0625","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221127547","article-title":"Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD","volume":"13","author":"Vilorio-Marqu\u00e9s","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"24","key":"10.1016\/j.blre.2026.101412_bb0630","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0635","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2026.101412_bb0640","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00277-019-03600-6","article-title":"Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients-a real-world experience from India","volume":"98","author":"Kanakasetty","year":"2019","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.blre.2026.101412_bb0645","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hon.2663","article-title":"Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy","volume":"37","author":"Bocchia","year":"2019","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.blre.2026.101412_bb0650","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.clml.2019.01.002","article-title":"Predictive model for infection risk in myelodysplastic syndromes, acute myeloid leukemia, and chronic Myelomonocytic leukemia patients treated with Azacitidine; Azacitidine infection risk model: the polish adult leukemia group study","volume":"19","author":"M\u0105dry","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.blre.2026.101412_bb0655","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/cam4.1231","article-title":"Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen","volume":"6","author":"Ali","year":"2017","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.blre.2026.101412_bb0660","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00277-017-3001-2","article-title":"A retrospective study evaluating the impact of infectious complications during azacitidine treatment","volume":"96","author":"Schuck","year":"2017","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.blre.2026.101412_bb0665","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1080\/10428194.2017.1295141","article-title":"Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes","volume":"58","author":"Trubiano","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0670","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1186\/s12885-017-3803-6","article-title":"Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens","volume":"17","author":"Seymour","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2026.101412_bb0675","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s00277-017-3091-x","article-title":"The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment","volume":"96","author":"Lorenzana","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2026.101412_bb0680","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2016.01.014","article-title":"Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: risk factors and efficacy of antibiotic prophylaxis","volume":"42","author":"Bainschab","year":"2016","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.blre.2026.101412_bb0685","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0690","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clml.2013.09.014","article-title":"Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis","volume":"14","author":"Falantes","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.blre.2026.101412_bb0695","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557","article-title":"Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy","volume":"124","author":"D\u00f6hner","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0700","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ajh.23368","article-title":"Predicting infections in high-risk patients with myelodysplastic syndrome\/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study","volume":"88","author":"Merkel","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0705","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2012.229","article-title":"The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison","volume":"27","author":"Burnett","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.blre.2026.101412_bb0710","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101412_bb0715","series-title":"Annual epidemiological reports","author":"ECDC","year":"2026"},{"issue":"4","key":"10.1016\/j.blre.2026.101412_bb0720","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/jac\/dky550","volume":"74","author":"Del Principe","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.blre.2026.101412_bb0725","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.1012334","article-title":"High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia","volume":"12","author":"Wang","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"8","key":"10.1016\/j.blre.2026.101412_bb0730","doi-asserted-by":"crossref","first-page":"E299","DOI":"10.1002\/ajh.26600","article-title":"Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia","volume":"97","author":"Jonas","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0735","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.clml.2020.08.013","article-title":"The incidence of invasive fungal infections in patients with AML treated with a Hypomethylating agent","volume":"21","author":"Ozga","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.blre.2026.101412_bb0740","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ajh.25808","article-title":"Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents","volume":"95","author":"GYG","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101412_bb0745","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720966882","article-title":"Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents","volume":"11","author":"Kang","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"10.1016\/j.blre.2026.101412_bb0750","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/myc.12500","article-title":"Invasive fungal infections in AML\/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?","volume":"59","author":"Pomares","year":"2016","journal-title":"Mycoses"},{"issue":"6","key":"10.1016\/j.blre.2026.101412_bb0755","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1200\/JCO.1997.15.6.2269","article-title":"Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Bergmann","year":"1997","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2026.101412_bb0760","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/cid\/ciaa090","article-title":"Differences and temporal changes in risk of invasive pneumococcal disease in adults with hematological malignancies: results from a Nationwide 16-year cohort study","volume":"72","author":"Andersen","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0765","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12967-017-1252-2","article-title":"Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy","volume":"15","author":"Goswami","year":"2017","journal-title":"J Transl Med"},{"issue":"30","key":"10.1016\/j.blre.2026.101412_bb0770","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1200\/JCO.19.00354","article-title":"Influenza vaccine effectiveness among patients with cancer: a population-based study using health administrative and laboratory testing data from Ontario, Canada","volume":"37","author":"Blanchette","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0775","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3324\/haematol.2022.280847","article-title":"COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)","volume":"108","author":"Marchesi","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0780","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/cancers16020379","article-title":"COVID-19 outcomes in patients with hematologic malignancies in the era of COVID-19 vaccination and the omicron variant","volume":"16","author":"Mart\u00ednez-L\u00f3pez","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.blre.2026.101412_bb0785","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1182\/bloodadvances.2021006333","article-title":"Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis","volume":"6","author":"Teh","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.blre.2026.101412_bb0790","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/bjc.2017.124","article-title":"Herpes zoster risk after 21 specific cancers: population-based case-control study","volume":"116","author":"Hansson","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2026.101412_bb0795","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12879-015-0810-6","article-title":"The epidemiology of herpes zoster and its complications in Medicare cancer patients","volume":"15","author":"Yenikomshian","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"11","key":"10.1016\/j.blre.2026.101412_bb0800","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1080\/21645515.2021.1930846","article-title":"Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview","volume":"17","author":"Dagnew","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.blre.2026.101412_bb0805","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ajh.27565","article-title":"Respiratory viruses in patients with hematological malignancy in boreal autumn\/winter 2023-2024: EPICOVIDEHA-EPIFLUEHA report","volume":"100","author":"Salmanton-Garc\u00eda","year":"2025","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0810","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ajh.70166","article-title":"Beyond the usual suspects: RSV infection in patients with hematological malignancies compared to influenza and SARS-COV-2-a report from the EPICOVIDEHA\/EPIRESEHA registry","volume":"101","author":"Salmanton-Garc\u00eda","year":"2026","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2026.101412_bb0815","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/S1470-2045(25)00765-X","volume":"27","author":"Mellinghoff","year":"2026","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.blre.2026.101412_bb0820","article-title":"High risk of hepatitis B reactivation among patients with acute myeloid leukemia","volume":"10","author":"Chen","year":"2015","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.blre.2026.101412_bb0825","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmi.2017.06.023","article-title":"Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper","volume":"23","author":"Sarmati","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.blre.2026.101412_bb0830","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.blre.2026.101412_bb0835","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.dld.2025.10.025","volume":"57","author":"Vigan\u00f2","year":"2025","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0840","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","author":"European Association for the Study of the Liver","year":"2025","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0845","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.blre.2026.101412_bb0850","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(25)00049-3","volume":"12","author":"Mikulska","year":"2025","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.blre.2026.101412_bb0855","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.cmi.2017.06.024","article-title":"Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review","volume":"23","author":"Gentile","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.blre.2026.101412_bb0860","article-title":"Breakthrough pneumocystis jirovecii pneumonia in an allogeneic hematopoietic stem cell transplant recipient","volume":"16","author":"Zieneldien","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.blre.2026.101412_bb0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106926","article-title":"Pneumocystis jirovecii pneumonia [PJP]: an unrecognized concern in AML patients on Venetoclax","volume":"121","author":"Rainchwar","year":"2022","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.blre.2026.101412_bb0870","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/myc.13411","article-title":"Pneumocystis jirovecii pneumonia in patients with previously untreated acute myeloid leukaemia","volume":"65","author":"Paterno","year":"2022","journal-title":"Mycoses"},{"issue":"1","key":"10.1016\/j.blre.2026.101412_bb0875","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/imj.13668","article-title":"Pneumocystis jirovecii pneumonia in patients with acute myeloid leukaemia","volume":"48","author":"Chang","year":"2018","journal-title":"Intern Med J"},{"key":"10.1016\/j.blre.2026.101412_bb0880","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijid.2014.04.030","article-title":"Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment","volume":"25","author":"Chang","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.blre.2026.101412_bb0885","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/bjh.19741","article-title":"Oral decitabine\/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: a randomised, crossover, registration, pharmacokinetics study","volume":"205","author":"Geissler","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101412_bb0890","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","article-title":"Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"Garcia-Manero","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2026.101412_bb0895","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(24)00033-4","article-title":"Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study","volume":"11","author":"Bazinet","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2026.101412_bb0900","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(23)00367-8","article-title":"Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-Centre, phase 1\/2 study","volume":"11","author":"Bataller","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2026.101412_bb0905","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101412_bb0910","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2026.101412_bb0915","series-title":"RP2D determination of bleximenib in combination with ven+aza: phase 1B study in nd & r\/r AML with KMT2A\/NPM1 alterations","author":"Wei","year":"2024"},{"issue":"s1","key":"10.1016\/j.blre.2026.101412_bb0920","article-title":"Phase 1 results: first-in-human phase 1\/2 study of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"14","author":"Zeidner","year":"2024","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:30:56Z","timestamp":1788258656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":184,"alternative-id":["S0268960X26000512"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101412","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101412"}}